Table 3. Cost, effectiveness and incremental cost-effectiveness ratio (vs. current scenario) by using PPSV–23 only.
| Vaccine cost per person | Treatment cost per person | Total cost per person | Effectiveness per person | Incremental cost | Incremental effectiveness | ICER* = (5)/(6) | |
|---|---|---|---|---|---|---|---|
| ¥ | ¥ | ¥ | QALY | ¥ | QALY | ||
| (1) | (2) | (3) = (1)+(2) | (4) | (5) | (6) | ||
| Current strategy | 3,860 | 20,456 | 24,316 | 14.31480 | - | - | - |
| 65–80 strategy | 2,259 | 20,460 | 22,719 | 14.31480 | -1,597 | -0.00001 | cost less, gain less |
| ≥65 strategy | 4,091 | 20,441 | 24,532 | 14.31485 | 216 | 0.00004 | 5025,000 |
*ICER: incremental cost-effectiveness ratio (¥/QALY gained). All ICERs were rounded to the nearest thousand.